Loading…
Contract research, development and manufacturing organization (CRDMO) serving global pharmaceutical companies.
Contract research, development and manufacturing organization (CRDMO) serving global pharmaceutical companies.
Charges for scientists' time on discovery work and for batches made in development and commercial supply, so it earns while its clients' drugs move from lab to market, with the manufacturing step growing as molecules succeed. It listed in India in 2024, and TPG, the private-equity firm that backed it, remains a major shareholder.
In one line: India's smaller Lonza/Catalent peer for pharma CRDMO services.
Moat: narrow (process know-how, customer qualification, regulatory licence). Regulatory-approved manufacturing facilities and long-term client relationships built through drug development cycles.
Headquarters: Hyderabad, India · Founded: 1999 · Employees: 5,227
Size SAI Life Sciences (SAILIFE.NS) is an India Industrials company (Miscellaneous Commercial Services) with a market value of $4.02B, the 241st largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,785 on 6 Nov 2026.
Performance Over six months the shares gained 63.8%, against +9.2% for the median peer and 0.0% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 27.4% over the last twelve months (peer median +7.0%); the operating margin is 21.5% (peer median 10.2%).
Valuation It trades at 89.2× forward earnings against a peer median of 14.4× (2nd most expensive of 19).
Capital Return on invested capital runs 5.0 points above its cost of capital (9.5% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹22.5B | ₹21.6B | ₹17.0B | ₹14.7B | ₹12.0B |
| Revenue growth | — | +27% | +15% | +23% | — |
| Gross profit | ₹7.98B | ₹5.77B | ₹4.23B | ₹2.90B | ₹1.50B |
| EBITDA | ₹6.58B | ₹6.05B | ₹4.14B | ₹2.98B | ₹1.51B |
| Net income | ₹3.62B | ₹3.49B | ₹1.70B | ₹828M | ₹99.9M |
| Free cash flow | n/a | -₹721M | -₹918M | ₹336M | ₹603M |
| Capital expenditure | n/a | ₹5.93B | ₹3.69B | ₹1.82B | ₹1.13B |
| Total debt | n/a | ₹2.88B | ₹3.52B | ₹9.28B | ₹9.33B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SAI Life Sciences SAILIFE.NS | $4.02B | +64% | +27% | 21% | 89.2× | n/a |
| Syngene International SYNGENE.NS | $1.78B | -11% | -6% | 13% | 67.8× | 35.3% |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SAILIFE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.3% | +3.7% | 5th highest of 21 |
| 6-month return | +63.8% | +9.2% | highest of 21 |
| Distance from 52-week high | -1.6% | -13.3% | highest of 21 |
| Revenue growth (TTM) | +27.4% | +7.0% | 6th highest of 21 |
| Operating margin | 21.5% | 10.2% | 4th highest of 21 |
| Forward P/E | 89.2× | 14.4× | 2nd most expensive of 19 |
| ROIC minus cost of capital | +5.0 pp | +3.7 pp | 7th highest of 18 |
| EV / EBITDA | 57.6× | 9.0× | 2nd most expensive of 16 |
| Net debt / EBITDA | 0.1× | 1.5× | 6th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SAI Life Sciences SAILIFE.NS | India | $4.02B | +64% | +27% | 21% | 89.2× | n/a | n/a |
| PhysicsWallah PWL.NS | India | $4.00B | +18% | +35% | 1% | 100.9× | n/a | n/a |
| Centre Testing International 300012.SZ | China | $3.96B | -5% | +15% | 16% | 22.1× | 14.2% | +13.2% |
| East Buy 1797.HK | Hong Kong | $4.11B | +22% | +34% | 11% | 38.5× | 18.4% | +54.3% |
| Alsok 2331.T | Japan | $3.79B | -1% | +7% | 8% | 13.7× | -6.0% | +4.9% |
| GEO GEO | United States | $3.66B | +28% | +15% | 12% | 13.5× | 6.8% | +2.3% |
| Serco SRP.L | United Kingdom | $3.60B | +5% | +1% | 5% | 14.9× | 1.9% | +4.9% |
| MITIE MTO.L | United Kingdom | $3.56B | +23% | +11% | 3% | 14.2× | 14.1% | +17.6% |
| Brink's BCO | United States | $4.54B | +3% | +7% | 10% | 11.8× | 0.1% | +7.3% |
| Teleperformance TEP.PA | France | $4.60B | +3% | -3% | 10% | 5.0× | -10.2% | +12.2% |
| Loomis LOOMIS.ST | Sweden | $3.46B | +12% | +1% | 11% | 12.6× | -9.1% | +9.7% |
| Dizal Pharmaceutical 688192.SS | China | $4.68B | +18% | +720% | 69% | 9.5× | -8.4% | +95.9% |
| MAXIMUS MMS | United States | $3.43B | +2% | -3% | 11% | 7.9× | -8.5% | +9.4% |
| L&T Technology Services LTTS.NS | India | $4.79B | +13% | +2% | 15% | 29.4× | 31.0% | +15.1% |
| Shenzhen Fortune Trend Technology 688318.SS | China | $3.36B | -21% | -3% | 56% | 69.5× | n/a | n/a |
| Aalberts AALB.AS | Netherlands | $4.87B | +6% | 0% | 10% | 14.6× | 12.9% | +3.4% |
| Jianshe Industry Group (Yunnan) 002265.SZ | China | $3.12B | -11% | +42% | 5% | n/a | 26.3% | +47.9% |
| ABM Industries ABM | United States | $3.10B | +32% | +6% | 5% | 12.5× | -2.0% | +7.9% |
| JHT Design 603061.SS | China | $3.07B | -8% | +93% | 34% | n/a | 43.9% | +30.4% |
| TriNet TNET | United States | $3.05B | +56% | -4% | 6% | 15.1× | -3.3% | +4.4% |
| FTI Consulting FCN | United States | $5.33B | +19% | +8% | 10% | 18.7× | -3.6% | +9.0% |